NewAmsterdam Pharma reported a net margin of -1,732.91% for the quarter ended Jun 2026. These financial ratios cover 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||
| EBT Margin | -486.94% | -2,230.11% | -1,602.62% | -6,160.40% | -6,692.86% | -1,711.58% | -57.19% | -721.71% | -1,327.30% | -90.70% | -20,691.09% | -234,134.38% | -1,593.45% | -1,732.91% | |
| EBIT Margin | -461.85% | -2,474.20% | -1,685.07% | -6,360.40% | -3,960.17% | -2,306.93% | -85.89% | -338.47% | -2,314.47% | -186.13% | -15,845.69% | -206,187.50% | -1,921.71% | -1,752.61% | |
| EBITDA Margin | -461.85% | -2,474.20% | -1,685.07% | -6,360.40% | -3,960.17% | -2,306.93% | -85.89% | -338.47% | -2,314.47% | -186.13% | -15,845.69% | -206,187.50% | -1,921.71% | -1,752.61% | |
| Operating Margin | -461.85% | -2,474.20% | -1,685.07% | -6,360.40% | -3,960.17% | -2,306.93% | -85.89% | -338.47% | -2,314.47% | -186.13% | -15,845.69% | -206,187.50% | -1,921.71% | -1,752.61% | |
| Net Margin | -486.94% | -2,230.11% | -1,602.62% | -6,160.40% | -6,692.86% | -1,711.58% | -57.18% | -721.71% | -1,327.30% | -90.70% | -20,691.09% | -234,134.38% | -1,593.45% | -1,732.91% | |
| FCF Margin | -369.34% | -1,707.05% | -1,597.59% | -4,119.18% | -3,924.84% | -2,377.71% | -43.20% | -293.49% | -1,225.12% | -197.23% | -9,428.45% | -128,046.88% | -1,007.96% | -1,061.71% | |
| Efficiency | |||||||||||||||
| Assets AverageAssets Avg. | 305.37M | 417.78M | 467.58M | 442.94M | 651.91M | 841.52M | 816.76M | 800.77M | 777.86M | 750.96M | 718.55M | ||||
| Invested CapitalInvested Cap. | 498.30M | 468.23M | 300.97M | 444.86M | 410.98M | 397.76M | 795.01M | 800.89M | 799.43M | 772.43M | 740.70M | 715.45M | 685.87M | ||
| Asset Utilization RatioAsset Util. | 0.02 | 0.02 | 0.08 | 0.07 | 0.06 | 0.08 | 0.04 | 0.03 | 0.03 | 0.01 | |||||
| Leverage & Solvency | |||||||||||||||
| Debt Ratio | 0.01 | 0.02 | 0.04 | 0.07 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.06 | 0.07 | 0.07 | 0.08 | ||
| Return Ratios | |||||||||||||||
| Return on Sales [ROS]ROS | -461.85% | -2,474.20% | -1,685.07% | -6,360.40% | -3,960.17% | -2,306.93% | -85.89% | -338.47% | -2,314.47% | -186.13% | -15,845.69% | -206,187.50% | -1,921.71% | -1,752.61% | |
| Return on Capital Employed [ROCE]ROCE | -55.47% | -49.42% | -45.84% | -32.35% | -23.70% | -22.15% | -27.33% | -32.61% | -31.48% | -37.86% | |||||
| Return on Assets [ROA]ROA | -54.73% | -49.06% | -44.90% | -37.06% | -22.26% | -20.29% | -27.61% | -26.20% | -28.33% | -36.12% |